Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus carboplatin and etoposide for advanced pulmonary large cell neuroendocrine carcinoma
jRCTs071240054Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, carboplatin and etoposide in large cell neuroendocrine carcinoma (LCNEC), sponsored by AstraZeneca. Primary endpoint: objective response rate. Started Sep 2024; status: recruiting.
02
Drugs
durvalumabcarboplatinetoposide
03
Conditions
large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on jRCTs071240054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071240054.